Abstract | OBJECTIVE: METHODS: RESULTS: CONCLUSION:
Fenebrutinib demonstrated efficacy comparable to adalimumab in patients with an inadequate response to methotrexate, and safety consistent with existing immunomodulatory therapies for RA. These data support targeting both B and myeloid cells via this novel mechanism for potential efficacy in the treatment of RA.
|
Authors | Stanley Cohen, Katie Tuckwell, Tamiko R Katsumoto, Rui Zhao, Joshua Galanter, Chin Lee, Julie Rae, Balazs Toth, Nandhini Ramamoorthi, Jason A Hackney, Alberto Berman, Nemanja Damjanov, Dmytro Fedkov, Slawomir Jeka, Leslie W Chinn, Michael J Townsend, Alyssa M Morimoto, Mark C Genovese |
Journal | Arthritis & rheumatology (Hoboken, N.J.)
(Arthritis Rheumatol)
(Apr 09 2020)
ISSN: 2326-5205 [Electronic] United States |
PMID | 32270926
(Publication Type: Journal Article)
|
Copyright | This article is protected by copyright. All rights reserved. |